LivaNova PLC ( (LIVN) ) has released its Q2 earnings. Here is a breakdown of the information LivaNova PLC presented to its investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
LivaNova PLC is a global medical technology company specializing in innovative solutions for neurological and cardiac conditions, with a strong presence in over 100 countries. In its latest earnings report, LivaNova announced a robust performance for the second quarter of 2025, marked by significant revenue growth and an upward revision of its full-year guidance. The company reported a 10.7% increase in revenue, reaching $352.5 million, and a notable rise in adjusted earnings per share to $1.05. LivaNova also initiated a process with the U.S. Centers for Medicare and Medicaid Services to reconsider national coverage for its VNS Therapy for treatment-resistant depression, highlighting its strategic focus on expanding its neuromodulation capabilities. Looking ahead, LivaNova has raised its full-year 2025 revenue growth expectations, projecting an 8.0% to 9.0% increase on a constant-currency basis, reflecting confidence in its continued market leadership and commitment to delivering life-changing therapies.